Barclays
TAK icon

Barclays’s Takeda Pharmaceutical TAK Stock Holding History

Barclays’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23K Sell
1,241
-10,896
-90% -$191K ﹤0.01% 4552
2025
Q4 		$189K Buy
12,137
+10,388
+594% +$149K ﹤0.01% 4353
2025
Q3 		$25.6K Buy
1,749
+172
+11% +$2.55K ﹤0.01% 4904
2025
Q2 		$24.4K Sell
1,577
-77
-5% -$1.14K ﹤0.01% 4822
2025
Q1 		$24.6K Buy
1,654
+709
+75% +$9.93K ﹤0.01% 4759
2024
Q4 		$12.5K Sell
945
-394
-29% -$5.41K ﹤0.01% 4969
2024
Q3 		$19K Buy
1,339
+1,337
+66,850% +$19K ﹤0.01% 4900
2024
Q2 		$26 Hold
2
– – ﹤0.01% 4776
2024
Q1 		$28 Hold
2
– – ﹤0.01% 5017
2023
Q4 		$28 Sell
2
-1,578
-100% -$22.4K ﹤0.01% 5189
2023
Q3 		$24.4K Sell
1,580
-50,256
-97% -$778K ﹤0.01% 4130
2023
Q2 		$814K Sell
51,836
-1,638,505
-97% -$26.8M ﹤0.01% 2443
2023
Q1 		$27.9M Buy
1,690,341
+3,200
+0.2% +$51K 0.01% 717
2022
Q4 		$26.3M Sell
1,687,141
-2,900
-0.2% -$40.5K 0.01% 760
2022
Q3 		$21.9M Buy
1,690,041
+3,069
+0.2% +$42.7K 0.02% 583
2022
Q2 		$23.7M Hold
1,686,972
– – 0.01% 645
2022
Q1 		$24.2M Buy
1,686,972
+246,199
+17% +$3.61M 0.02% 621
2021
Q4 		$19.6M Sell
1,440,773
-41,087
-3% -$576K 0.01% 950
2021
Q3 		$24.3M Buy
1,481,860
+433,930
+41% +$7.28M 0.01% 809
2021
Q2 		$17.6M Buy
1,047,930
+465,182
+80% +$7.92M 0.01% 946
2021
Q1 		$10.6M Buy
582,748
+429,929
+281% +$7.74M 0.01% 1060
2020
Q4 		$2.78M Sell
152,819
-149,627
-49% -$2.63M ﹤0.01% 1981
2020
Q3 		$5.39M Sell
302,446
-645
-0.2% -$11.7K ﹤0.01% 1350
2020
Q2 		$5.43M Sell
303,091
-35,864
-11% -$644K ﹤0.01% 1315
2020
Q1 		$5.14M Sell
338,955
-71,157
-17% -$1.29M ﹤0.01% 1441
2019
Q4 		$8.09M Sell
410,112
-24,100
-6% -$461K ﹤0.01% 1563
2019
Q3 		$7.47M Buy
434,212
+128,577
+42% +$2.22M ﹤0.01% 1531
2019
Q2 		$5.41M Buy
305,635
+52,076
+21% +$948K ﹤0.01% 1798
2019
Q1 		$5.17M Buy
253,559
+232,058
+1,079% +$4.67M ﹤0.01% 1641
2018
Q4 		$362K Buy
+21,501
New +$363K ﹤0.01% 4117

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's TAK Position: Q1 2026 in Review

Barclays reduced its Takeda Pharmaceutical (TAK) stake by 90% in Q1 2026, selling an estimated $191K and leaving 1,241 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #4552.

Barclays first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $27.9M in Q1 2023. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Barclays held 1,241 shares of Takeda Pharmaceutical worth $23K as of Q1 2026.
  • Barclays sold 10,896 Takeda Pharmaceutical shares in Q1 2026, an estimated $191K.
  • Takeda Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4552 holding.
  • Barclays first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • Barclays's Takeda Pharmaceutical position peaked at $27.9M in Q1 2023.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.